MBX
MBX Biosciences, Inc. Common Stock
NASDAQ: MBX · HEALTHCARE · BIOTECHNOLOGY
$28.61
-1.48% today
Updated 2026-04-29
Market cap
$1.38B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.38
Dividend yield
—
52W range
$9 – $45
Volume
0.5M
MBX Biosciences, Inc. Common Stock (MBX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — |
| Cost of revenue | $56000.00 | $157000.00 | $244000.00 | $248000.00 |
| Gross profit | $-56000.00 | $-157000.00 | $-244000.00 | $-248000.00 |
| Gross margin | — | — | — | — |
| R&D | $21.40M | $28.53M | $57.41M | $79.16M |
| SG&A | $3.76M | $6.78M | $10.78M | $18.90M |
| Operating income | $-25.16M | $-35.31M | $-68.19M | $-98.06M |
| Operating margin | — | — | — | — |
| EBITDA | $-25.70M | $-35.15M | $-67.95M | $-98.06M |
| EBITDA margin | — | — | — | — |
| EBIT | $-25.76M | $-35.31M | $-68.19M | $-98.30M |
| Interest expense | $374000.00 | $0.00 | — | — |
| Income tax | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-26.14M | $-32.56M | $-61.92M | $-86.97M |
| Net income growth (YoY) | — | -24.6% | -90.2% | -40.5% |
| Profit margin | — | — | — | — |